Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Alan Newman who wrote (5953)	11/19/1998 8:19:00 PM
From: Linda Kaplan	Respond to of 7041

Alan, On Mexico, it means they overstuffed the channel at the beginning and the sales in the beginning that people were getting excited about weren't sell-through sales. That is, the stores bought, but didn't sell through to customers. So those sales were at minimum double the truth, and possibly even worse than that. They may have future sales, but the initial sales were misleading and were not sustainable -- future sales will be fractional what they seemed to be in the first quarter, if there are any at all. If they are pinning their hopes on Vasomax, then the company will be folding even if the drug is approved, because sales will be negligible. That is what I've been saying and that is what the numbers support: NEGLIGIBLE to NO SALES! Thanks so much for reviewing the 10Q. I really appreciate it. Everything in the fundamentals supports shorting this stock. --Linda